[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA52202A - Compositions d'érénumab et utilisations de celles-ci - Google Patents

Compositions d'érénumab et utilisations de celles-ci

Info

Publication number
MA52202A
MA52202A MA052202A MA52202A MA52202A MA 52202 A MA52202 A MA 52202A MA 052202 A MA052202 A MA 052202A MA 52202 A MA52202 A MA 52202A MA 52202 A MA52202 A MA 52202A
Authority
MA
Morocco
Prior art keywords
erenumab
compositions
Prior art date
Application number
MA052202A
Other languages
English (en)
Inventor
Suminda Hapuarachchi
Kenneth Lawson
Jose Gregorio Ramirez
Noel Rieder
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA52202A publication Critical patent/MA52202A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/26—Conditioning of the fluid carrier; Flow patterns
    • G01N30/38—Flow patterns
    • G01N30/46—Flow patterns using more than one column
    • G01N30/461—Flow patterns using more than one column with serial coupling of separation columns
    • G01N30/463—Flow patterns using more than one column with serial coupling of separation columns for multidimensional chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA052202A 2018-04-02 2019-04-01 Compositions d'érénumab et utilisations de celles-ci MA52202A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862651651P 2018-04-02 2018-04-02

Publications (1)

Publication Number Publication Date
MA52202A true MA52202A (fr) 2021-02-17

Family

ID=66248665

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052202A MA52202A (fr) 2018-04-02 2019-04-01 Compositions d'érénumab et utilisations de celles-ci

Country Status (19)

Country Link
US (2) US11407838B2 (fr)
EP (1) EP3774881A1 (fr)
JP (2) JP2021519790A (fr)
KR (1) KR20200139720A (fr)
CN (1) CN111954678A (fr)
AR (1) AR114722A1 (fr)
AU (1) AU2019246983A1 (fr)
BR (1) BR112020019882A2 (fr)
CA (1) CA3095899A1 (fr)
CL (2) CL2020002519A1 (fr)
EA (1) EA202092335A1 (fr)
IL (1) IL277663A (fr)
MA (1) MA52202A (fr)
MX (1) MX2020010320A (fr)
PH (1) PH12020551618A1 (fr)
SA (1) SA520420261B1 (fr)
SG (1) SG11202009629YA (fr)
TW (1) TWI847980B (fr)
WO (1) WO2019195185A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP4455163A1 (fr) * 2021-12-22 2024-10-30 Chugai Seiyaku Kabushiki Kaisha Variant d'anticorps à activité biologique réduite

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
WO1990003430A1 (fr) 1988-09-23 1990-04-05 Cetus Corporation Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JPH07504802A (ja) 1992-03-17 1995-06-01 ノバルティス　アクチェンゲゼルシャフト 遺伝子操作抗体
ATE265466T1 (de) 1994-08-16 2004-05-15 Human Genome Sciences Inc Calcitoninrezeptor
US5785682A (en) 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
WO1998003534A1 (fr) 1996-07-23 1998-01-29 Smithkline Beecham Corporation Facteur composant du recepteur du peptide apparente au gene de la calcitonine (houdc44)
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
PT1308456E (pt) 1998-05-06 2007-12-03 Genentech Inc Purificação de anticorpos por cromatografia de permuta iónica
CA2333747C (fr) 1998-06-01 2008-02-19 Genentech, Inc. Separation des monomeres proteiques des agregats par l'utilisation de la chromatographie d'echange d'ions
FR2821080B1 (fr) 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
DE60234944D1 (de) 2001-09-27 2010-02-11 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodiered assayverfahren
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
RS52750B (sr) 2002-08-12 2013-08-30 Birkir Sveinsson Upotreba cgrp antagonista za lečenje psorijaze
US20040176577A1 (en) 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (fr) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics et traitements destines a des maladies associees au recepteur de type recepteur calcitonine (calcrl)
KR20140011431A (ko) 2004-02-11 2014-01-28 아밀린 파마슈티칼스, 엘엘씨. 선택가능한 특성을 갖는 하이브리드 폴리펩티드
JP5553963B2 (ja) 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
EP1805205A1 (fr) 2004-10-22 2007-07-11 Amgen Inc. Methodes de repliement de polypeptides
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
NZ556029A (en) 2004-12-21 2010-04-30 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
CN101232897A (zh) 2005-06-16 2008-07-30 新藤隆行 含有肾上腺髓质素作为有效成分的血管生成剂
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
CN103421114B (zh) 2005-11-14 2017-09-22 莱布瑞斯生物公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
WO2007076336A1 (fr) 2005-12-22 2007-07-05 Eli Lilly And Company Traitement de la migraine avec des anticorps anti-cgrp
CN101553505B (zh) 2006-08-03 2013-07-17 阿斯利康(瑞典)有限公司 针对αVβ6的抗体及其应用
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
ES2584907T3 (es) 2008-03-04 2016-09-30 Labrys Biologics Inc. Métodos para tratamiento del dolor inflamatorio
FR2934597B1 (fr) 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
AU2009316592B2 (en) * 2008-11-20 2016-01-07 Genentech, Inc. Therapeutic protein formulations
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
AU2010221156A1 (en) * 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
SG178078A1 (en) * 2009-07-24 2012-03-29 Hoffmann La Roche Optimizing the production of antibodies
EP2470207A1 (fr) 2009-08-28 2012-07-04 Rinat Neuroscience Corporation Procédés de traitement de la douleur viscérale par administration d'anticorps antagonistes dirigés contre le peptide associé au gène de la calcitonine
PT2513134T (pt) 2009-12-18 2017-12-14 Novartis Ag Solução de lavagem e método para cromatografia de afinidade
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
KR101965461B1 (ko) 2011-05-20 2019-04-04 앨더바이오 홀딩스 엘엘씨 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
EP2726496B1 (fr) 2011-07-01 2018-04-04 F.Hoffmann-La Roche Ag Procédé de séparation des polypeptides monomères de polypeptides agrégés
MX2014006673A (es) * 2011-12-07 2014-09-04 Amgen Inc Separacion de la isoforma de disulfuro de la igg2.
JP6092892B2 (ja) * 2011-12-15 2017-03-08 プレステージ バイオファーマ プライベート リミテッド 抗体の精製方法
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
AU2014228924B2 (en) 2013-03-15 2019-04-18 Amgen Inc. Human PAC1 antibodies
SI3019516T1 (sl) * 2013-07-12 2019-02-28 F. Hoffmann-La Roche Ag Določitev optimalnih vhodnih parametrov za ionsko izmenjevalno kromatografijo
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
UA123759C2 (uk) 2014-03-21 2021-06-02 Тева Фармасьютікалз Інтернешнл Гмбх Застосування моноклонального антитіла, яке інгібує шлях пов'язаного з геном кальциноніну пептиду (cgrp), для лікування або зниження частоти випадків мігренозного головного болю у суб'єкта
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CA2960756C (fr) 2014-09-15 2023-08-01 Amgen Inc. Proteines de liaison antigeniques bispecifiques anti-recepteur cgrp/recepteur pac1 et leurs utilisations
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp

Also Published As

Publication number Publication date
CL2020002519A1 (es) 2021-04-05
TWI847980B (zh) 2024-07-11
US20190300617A1 (en) 2019-10-03
WO2019195185A1 (fr) 2019-10-10
AU2019246983A1 (en) 2020-10-29
EP3774881A1 (fr) 2021-02-17
JP2023103323A (ja) 2023-07-26
JP2021519790A (ja) 2021-08-12
PH12020551618A1 (en) 2021-08-16
BR112020019882A2 (pt) 2021-01-05
EA202092335A1 (ru) 2021-01-22
KR20200139720A (ko) 2020-12-14
AR114722A1 (es) 2020-10-07
CA3095899A1 (fr) 2019-10-10
TW202003572A (zh) 2020-01-16
US11407838B2 (en) 2022-08-09
IL277663A (en) 2020-11-30
SA520420261B1 (ar) 2024-05-23
CN111954678A (zh) 2020-11-17
SG11202009629YA (en) 2020-10-29
US20220348673A1 (en) 2022-11-03
CL2023000491A1 (es) 2023-10-13
MX2020010320A (es) 2021-01-08

Similar Documents

Publication Publication Date Title
MA50753A (fr) Compositions d'acide nucléique-polypeptide et utilisations de celles-ci
MA46990A (fr) Compositions de glp-1 et leurs utilisations
MA51288A (fr) Analogues d'incrétine et leurs utilisations
SG11202100214SA (en) Antagonists of t2r54 and compositions and uses thereof
JP2018172409A5 (ja) １５−ｈｅｐｅを含む組成物および同組成物を使用する方法
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
MA51287A (fr) Analogues d'incrétine et leurs utilisations
MA44991A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-1
MA43709A (fr) Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
MA49403A (fr) Compositions de pde5 et méthodes d'immunothérapie
MA46525A (fr) Anticorps anti-lag-3 et compositions
PL3668937T3 (pl) Kompozycje i zastosowania Z-1-chloro-2,3,3,3-tetrafluoroprop-1-enu
MA46389A (fr) Variants de l'endonucléase homing pd1, compositions et procédés d'utilisation
MA45996A (fr) Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
MA51066A (fr) Inhibiteurs d'intégrine
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
MA48797A (fr) Variants de l'endonucléase cblb , compositions et procédés d'utilisation
MA49047A (fr) Composés inhibiteurs d'ask1 et utilisations associées
MA50465A (fr) Compositions de peptides tau phosphorylés et leurs utilisations
MA47494A (fr) Nouvelles utilisations d'anticorps anti-sirpg
MA46672A (fr) Immunoglobulines et utilisations de celles-ci
MA52637A (fr) Compositions de lutte contre les agents pathogènes et leurs utilisations
MA50145A (fr) Composés inhibiteurs de vmat2 et compositions de ceux-ci
MA52337A (fr) Nouveaux analogues d'oxaborole et utilisations de ces derniers